Literature DB >> 8169008

Cytotoxic T lymphocytes recognize tumor antigens of a murine colonic carcinoma by using different T-cell receptors.

M Rodolfo1, C Castelli, C Bassi, P Accornero, M Sensi, G Parmiani.   

Abstract

To see whether different antigens expressed by the same tumor are recognized by distinct T-cell receptors (TCR), we used cytotoxic T-lymphocyte (CTL) lines known to lyse in vitro the syngeneic BALB/c adenocarcinoma C-26. Four of these CD3+ CD8+ lines showed 4 different patterns of lysis on a panel of MHC-class-I-compatible targets. The activity was H-2d-restricted and could be blocked by anti-CD3 and anti-TCR-alpha/beta monoclonal antibodies (MAbs). The CTL lines were also effective, although to a different extent, in adoptive immunotherapy of mice bearing lung metastases. Phenotypic analysis revealed in all the lines a high frequency of cells positive for CD45, asialo GM1 (ASGM1), lymphocyte-function-associated antigen-1 (LFA-1), intercellular adhesion molecule-1 (ICAM-1) and CD44, but negligible expression of L-selectin (LAM-1) and very late antigen-4 (VLA-4); 2 lines expressed the vitronectin-receptor (VN-R). Analysis of TCR V beta-chains used by the 4 lines showed selective presence of V beta 6, V beta 8.2, V beta 8.3 and of V beta 13 chains. MAbs directed to these V beta chains blocked their lytic activity in vitro. V alpha-chain transcripts of the lines were identified by polymerase chain reaction (PCR) as V alpha ITT11 and V alpha 52 in 2 lines, while one could not be identified. Analysis of V beta s in mixed lymphocyte-tumor-cell cultures (MLTC) of T cells deriving from tumor-infiltrating lymphocytes (TIL) or from spleen of C-26 tumor-bearing or immune animals indicated that the TCR of the CTL lines were representatives of the TCR repertoire recognizing C-26 tumor, since their V beta s were shown to be selectively expanded in MLTC.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 8169008     DOI: 10.1002/ijc.2910570324

Source DB:  PubMed          Journal:  Int J Cancer        ISSN: 0020-7136            Impact factor:   7.396


  6 in total

1.  Dendritic cells infiltrating tumors cotransduced with granulocyte/macrophage colony-stimulating factor (GM-CSF) and CD40 ligand genes take up and present endogenous tumor-associated antigens, and prime naive mice for a cytotoxic T lymphocyte response.

Authors:  C Chiodoni; P Paglia; A Stoppacciaro; M Rodolfo; M Parenza; M P Colombo
Journal:  J Exp Med       Date:  1999-07-05       Impact factor: 14.307

2.  Relating TCR-peptide-MHC affinity to immunogenicity for the design of tumor vaccines.

Authors:  Rachel H McMahan; Jennifer A McWilliams; Kimberly R Jordan; Steven W Dow; Darcy B Wilson; Jill E Slansky
Journal:  J Clin Invest       Date:  2006-08-24       Impact factor: 14.808

3.  Cancer-associated immunodeficiency and dendritic cell abnormalities mediated by the prostaglandin EP2 receptor.

Authors:  Li Yang; Noboru Yamagata; Rajwardhan Yadav; Suzanne Brandon; Regina L Courtney; Jason D Morrow; Yu Shyr; Mark Boothby; Sebastian Joyce; David P Carbone; Richard M Breyer
Journal:  J Clin Invest       Date:  2003-03       Impact factor: 14.808

4.  In vivo evaluation of the early events associated with liver metastasis of circulating cancer cells.

Authors:  L Ding; M Sunamura; T Kodama; J Yamauchi; D G Duda; H Shimamura; K Shibuya; K Takeda; S Matsuno
Journal:  Br J Cancer       Date:  2001-08-03       Impact factor: 7.640

5.  The nonpolymorphic MHC Qa-1b mediates CD8+ T cell surveillance of antigen-processing defects.

Authors:  Cláudia C Oliveira; Peter A van Veelen; Bianca Querido; Arnoud de Ru; Marjolein Sluijter; Sandra Laban; Jan W Drijfhout; Sjoerd H van der Burg; Rienk Offringa; Thorbald van Hall
Journal:  J Exp Med       Date:  2009-12-28       Impact factor: 14.307

6.  Interferon gamma-independent rejection of interleukin 12-transduced carcinoma cells requires CD4+ T cells and Granulocyte/Macrophage colony-stimulating factor.

Authors:  C Zilocchi; A Stoppacciaro; C Chiodoni; M Parenza; N Terrazzini; M P Colombo
Journal:  J Exp Med       Date:  1998-07-06       Impact factor: 14.307

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.